336 related articles for article (PubMed ID: 21960059)
1. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.
Nakatani F; Ferracin M; Manara MC; Ventura S; Del Monaco V; Ferrari S; Alberghini M; Grilli A; Knuutila S; Schaefer KL; Mattia G; Negrini M; Picci P; Serra M; Scotlandi K
J Pathol; 2012 Apr; 226(5):796-805. PubMed ID: 21960059
[TBL] [Abstract][Full Text] [Related]
2. Ewing's Sarcoma: An Analysis of miRNA Expression Profiles and Target Genes in Paraffin-Embedded Primary Tumor Tissue.
Parafioriti A; Bason C; Armiraglio E; Calciano L; Daolio PA; Berardocco M; Di Bernardo A; Colosimo A; Luksch R; Berardi AC
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27144561
[TBL] [Abstract][Full Text] [Related]
3. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.
Le Deley MC; Delattre O; Schaefer KL; Burchill SA; Koehler G; Hogendoorn PC; Lion T; Poremba C; Marandet J; Ballet S; Pierron G; Brownhill SC; Nesslböck M; Ranft A; Dirksen U; Oberlin O; Lewis IJ; Craft AW; Jürgens H; Kovar H
J Clin Oncol; 2010 Apr; 28(12):1982-8. PubMed ID: 20308673
[TBL] [Abstract][Full Text] [Related]
4. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.
Bacci G; Ferrari S; Bertoni F; Rimondini S; Longhi A; Bacchini P; Forni C; Manfrini M; Donati D; Picci P
J Clin Oncol; 2000 Jan; 18(1):4-11. PubMed ID: 10623687
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression.
Marino MT; Grilli A; Baricordi C; Manara MC; Ventura S; Pinca RS; Bellenghi M; Calvaruso M; Mattia G; Donati D; Tripodo C; Picci P; Ferrari S; Scotlandi K
Ann Oncol; 2014 Oct; 25(10):2080-2086. PubMed ID: 25015333
[TBL] [Abstract][Full Text] [Related]
8. Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma.
Yang Y; Li H; Zhang F; Shi H; Zhen T; Dai S; Kang L; Liang Y; Wang J; Han A
J Pathol; 2013 Nov; 231(3):323-34. PubMed ID: 23878072
[TBL] [Abstract][Full Text] [Related]
9. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.
de Alava E; Kawai A; Healey JH; Fligman I; Meyers PA; Huvos AG; Gerald WL; Jhanwar SC; Argani P; Antonescu CR; Pardo-Mindan FJ; Ginsberg J; Womer R; Lawlor ER; Wunder J; Andrulis I; Sorensen PH; Barr FG; Ladanyi M
J Clin Oncol; 1998 Apr; 16(4):1248-55. PubMed ID: 9552022
[TBL] [Abstract][Full Text] [Related]
10. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
[TBL] [Abstract][Full Text] [Related]
11. Decreased levels of miR-34a and miR-217 act as predictor biomarkers of aggressive progression and poor prognosis in hepatocellular carcinoma.
Tian YW; Shen Q; Jiang QF; Wang YX; Li K; Xue HZ
Minerva Med; 2017 Apr; 108(2):108-113. PubMed ID: 27879964
[TBL] [Abstract][Full Text] [Related]
12. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
Tural D; Molinas Mandel N; Dervisoglu S; Oner Dincbas F; Koca S; Colpan Oksuz D; Kantarci F; Turna H; Selcukbiricik F; Hiz M
Jpn J Clin Oncol; 2012 May; 42(5):420-6. PubMed ID: 22416252
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-301a promotes cell proliferation via PTEN targeting in Ewing's sarcoma cells.
Kawano M; Tanaka K; Itonaga I; Iwasaki T; Tsumura H
Int J Oncol; 2016 Apr; 48(4):1531-40. PubMed ID: 26846737
[TBL] [Abstract][Full Text] [Related]
14. Analysis of prognostic factors of pediatric-type sarcomas in adult patients.
Ahn HK; Uhm JE; Lee J; Lim DH; Seo SW; Sung KS; Lee SJ; Lee DJ; Baek KK; Kim WS; Park JO
Oncology; 2011; 80(1-2):21-8. PubMed ID: 21606660
[TBL] [Abstract][Full Text] [Related]
15. Nutlin-3a is a potential therapeutic for ewing sarcoma.
Pishas KI; Al-Ejeh F; Zinonos I; Kumar R; Evdokiou A; Brown MP; Callen DF; Neilsen PM
Clin Cancer Res; 2011 Feb; 17(3):494-504. PubMed ID: 21098696
[TBL] [Abstract][Full Text] [Related]
16. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.
Nagano A; Ohno T; Shimizu K; Hara A; Yamamoto T; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Takei Y
Int J Cancer; 2010 Jun; 126(12):2790-8. PubMed ID: 19642105
[TBL] [Abstract][Full Text] [Related]
17. Identification of Four Oxidative Stress-Responsive MicroRNAs, miR-34a-5p, miR-1915-3p, miR-638, and miR-150-3p, in Hepatocellular Carcinoma.
Wan Y; Cui R; Gu J; Zhang X; Xiang X; Liu C; Qu K; Lin T
Oxid Med Cell Longev; 2017; 2017():5189138. PubMed ID: 28811864
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in patients with localized Ewing's sarcoma: the effect on survival of actual received drug dose intensity and of histologic response to induction therapy.
Delepine N; Delepine G; Cornille H; Voisin MC; Brun B; Desbois JC
J Chemother; 1997 Oct; 9(5):352-63. PubMed ID: 9373791
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
Brunetto AL; Castillo LA; Petrilli AS; Macedo CD; Boldrini E; Costa C; Almeida MT; Kirst D; Rodriguez-Galindo C; Pereira WV; Watanabe FM; Pizza M; Benites E; Morais V; Gadelha A; Nakasato A; Abujamra AL; Gregianin LJ;
Pediatr Blood Cancer; 2015 Oct; 62(10):1747-53. PubMed ID: 25917418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
